Halozyme therapeutics to Present at the Roth Capital Partners 19th Annual OC Conference
February 13 2007 - 8:00AM
PR Newswire (US)
SAN DIEGO, Feb. 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics,
Inc. (AMEX:HTI), a biopharmaceutical company developing and
commercializing recombinant human enzymes, today announced that it
will present at the Roth Capital Partners 19th Annual OC Conference
to be held at The Ritz Carlton in Laguna Niguel, Calif., on
February 19-22, 2007. Jonathan Lim, MD, Halozyme's President and
Chief Executive Officer, will present on Wednesday, February 21,
2007 at 5:00 p.m. Pacific time (8:00 p.m. Eastern time) and will
discuss the Company's strategic initiatives, product pipeline and
market opportunities. Interested parties can access a live audio
webcast and accompanying slide presentation via the Internet by
visiting the Investor Relations section of the Company's Web site
at http://www.halozyme.com/. An archived presentation will be
available on the Web site for 30 days. About Halozyme Therapeutics,
Inc. Halozyme is a biopharmaceutical company developing and
commercializing recombinant human enzymes for the drug delivery,
palliative care, oncology, and infertility markets. The company's
portfolio of products is based on intellectual property covering
the family of human enzymes known as hyaluronidases. The company's
Enhanze(TM) Technology is a novel drug delivery platform designed
to increase the absorption and dispersion of biologics. Its first
partnership is with Roche to apply Enhanze Technology to Roche's
biological therapeutic compounds for 13 targets. In addition, the
company has received FDA approval for two products: Cumulase(R) and
Hylenex, for use as an adjuvant to increase the absorption and
dispersion of other injected drugs and fluids. The Company also has
a number of different enzymes in its portfolio that are targeting
significant areas of unmet need. Halozyme Contact Investor
Relations Contact David A. Ramsay Don Markley Chief Financial
Officer Lippert/Heilshorn & Associates (858) 794-8881 (310)
691-7100 DATASOURCE: Halozyme Therapeutics, Inc. CONTACT: David A.
Ramsay, Chief Financial Officer of Halozyme Therapeutics, Inc.,
+1-858-794-8881, ; or Investor Relations, Don Markley of
Lippert/Heilshorn & Associates, +1-310-691-7100, , for Halozyme
Therapeutics, Inc. Web site: http://www.halozyme.com/
Copyright
Halozyme Therapeutic (AMEX:HTI)
Historical Stock Chart
From Apr 2024 to May 2024
Halozyme Therapeutic (AMEX:HTI)
Historical Stock Chart
From May 2023 to May 2024